

PO Number	
1	Dissolution of NSAIDS in physiological relevant buffer: implications for biowaiver
	<u>Haili Ping</u> and Gordon Amidon
	<i>Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI USA</i>
8	Biphasic gastric emptying theory as a possible explanation of multiple peaks phenomenon
	<u>Won-Sik Shim</u> , Yun Kyung Lee, and Chang-Koo Shim
	<i>National Research Laboratory of Transporters Targeted Drug Design, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea</i>
12	Intestinal and liver CYP3A4-mediated metabolism of R/S-verapamil in pigs
	<u>Helena Eriksson</u> ¹ , Paul Dickinson ² , and Hans Lennernäs ¹
	<i>¹Department of pharmacy, Uppsala University, Sweden, and ²Pharmaceutical and Analytical Research & Development, AstraZeneca, Alderley Park, Cheshire, England</i>

17	Backbone cyclization of a melanocortin-4 agonist enhances its intestinal permeability and yields a novel peptide drug candidate for treating obesity
	Oded Ovadia ¹ , Shmuel Hess ¹ , Yaniv Linde ² , Carrie Haskell-Luevano ³ , Chaim Gilon ² , and <u>Amnon Hoffman</u> ¹
	<i>¹Pharmaceutics and ² Organic Chemistry Departments, The Hebrew University of Jerusalem, Israel, and ³ Department of Medicinal Chemistry, University of Florida, Gainesville, Florida, USA</i>
18	Effect of glycerol-related compounds on carrier-mediated glycerol uptake in HCT-15 cells
	<u>Nami Fujimoto</u> ¹ , Katsuhisa Inoue ¹ , Yayoi Hayashi ² , and Hiroaki Yuasa ¹
	<i>¹Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan, and ²College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan</i>
25	TRN classification of ampicillin prodrugs for P-glycoprotein using Caco-2 cells for designing absorbable lipophilic prodrugs
	<u>Takashi Mizuma</u> , Sachie Tanaami, Sayaka Sakaguchi, and Masahiro Hayashi
	<i>School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan</i>
28	Change in the localization of tight junction proteins in the plasma membrane of an MDCK monolayer by treatment with a medium-chain fatty acid

	<u>Yoshinori Onuki</u> , Ko Sugibayashi, and Kozo Takayama
	<i>Department of Pharmaceutics, Hoshi University, Tokyo, Japan</i>
34	Mechanisms of membrane transport of poorly soluble drugs: Role of micelles in oral absorption processes
	<u>Koji Yano</u> , Yoshie Masaoka, Makoto Kataoka, Shinji Sakuma, and Shinji Yamashita
	<i>Setsunan University, Hirakata, Osaka, Japan</i>
35	Multiple inhibition mechanism of ketoconazole on activities of CYP3A4 and P-glycoprotein
	Yun-Ping Lim, and <u>Jin-ding Huang</u>
	<i>Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan</i>
38	Prediction of human intestinal availability of CYP3A4 substrates based on in vitro studies
	<u>Yumiko Iwase</u> , Masataka Ishiji, Yasuyuki Tsuda, and Tomoo Itoh

	<i>School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.</i>
44	Simulation of non-linear dose dependent absorption and pharmacodynamic response of P-glycoprotein substrate talinolol
	<u>Marija Tubic-Grozdanis</u> , Hildegard Spahn-Langguth, and Peter Langguth
	<i>Department of Biopharmaceutics and Pharmaceutical Technology, Johannes-Gutenberg University, Mainz, Germany</i>
45	A simulation study to clarify the impact of uneven distribution of CYP3A4 and P-glycoprotein in intestine on barrier function against xenobiotics
	<u>Kazuya Maeda</u> , Takao Watanabe, Chikako Nakai, and Yuichi Sugiyama
	<i>Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan</i>
46	A Novel Physiologically-Based Mechanistic Model for Predicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model
	<u>Masoud Jamei</u> ¹ , Jiansong Yang ¹ , David Turner ¹ , Karen R. Yeo ¹ , Geoffrey T. Tucker ^{1,2} , and Amin Rostami-Hodjegan ^{1,2}
	¹ <i>Simcyp Limited, Blades Enterprise Centre, John Street, Sheffield, United Kingdom, and</i> ² <i>Academic Unit of Clinical Pharmacology, Pharmacokinetics and Pharmacogenetics Group, University of Sheffield, United Kingdom</i>

49	Systematic prediction of drug-drug interactions mediated by CYP3A4 from <i>in vivo</i> pharmacokinetics; considerations on intestinal metabolism and transport
	<u>Akihiro Hisaka</u> , Yoshiyuki Ohno, and Hiroshi Suzuki
	<i>The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan</i>
53	Cranberry juice affects the pharmacokinetics of tadalafil in rats
	<u>Ching-Ling Cheng</u> ¹ , Yu-Shuan Chen ² , and Chen-Hsi Chou ²
	¹ <i>Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Jen-Te, Tainan, Taiwan, and</i> ² <i>Institute of Clinical Pharmacy, Medical College, National Cheng Kung University, Tainan, Taiwan.</i>
59	Pharmacokinetics of pyrazinamide and pyrazinoic acid and the interaction with silibinin in rats
	Jhy-Wen Wu ^{1,2} , and <u>Tung-Hu Tsai</u> ^{1,3}
	¹ <i>Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, </i> ² <i>Centers for Disease Control, Department of Health, Taipei, Taiwan, and </i> ³ <i>Department of Education and Research, Taipei City Hospital, Taipei, Taiwan</i>
62	Predominant contribution of rat oatp2 to hepatic uptake of β-lactam antibiotics

	<u>Masanori Nakakariya</u> ¹ , Taiki Shimada ¹ , Masanori Irokawa ¹ , Hiroyuki Koibuchi ¹ , Takashi Iwanaga ¹ , Hikaru Yabuuchi ² , Tomoji Maeda ¹ , and Ikumi Tamai ¹
	¹ <i>Department of Membrane Transport and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan, and</i> ² <i>GenoMembrane, Inc., Kanagawa, Japan.</i>
67	Site-directed mutagenesis study on drug binding specificity to genetic variants of human α_1-acid glycoprotein
	<u>Toru Maruyama</u> , Megumi Ueno, Koji Nishi, Yuka Murakami, Naoko Fukunaga, Teruo Akuta, Hitoshi Watanabe, Yasunori Iwao, Ayaka Suenaga, and Masaki Otagiri
	<i>Kumamoto University, Kumamoto, Japan</i>
70	Targeted delivery of NFkB decoy by glycosylated cationic liposomes
	<u>Shigeru Kawakami</u> , Yuriko Higuchi, and Mitsuru Hashida
	<i>Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan</i>
78	Structural requirements for drug inhibition of human OCT1
	<u>Gustav Ahlin</u> ¹ , Johan Karlsson ² , Lena Gustavsson ³ , Jenny Olofsson ¹ , Constanze Hilgendorf ² , Christel Bergström ¹ , and Per Artursson ¹

	<i>¹Department of Pharmacy, Uppsala University, Sweden, ²AstraZeneca, Mölndal, Sweden, and ³AstraZeneca, Lund, Sweden</i>
81	Functional validation of genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1): The functional impact of tetra-allelic SNPs 2677G>T, A, or C
	Aki Sakurai ^{1,2} , Yuko Onishi ¹ , Ei Leen Liew ¹ , Hiroyuki Hirano ¹ , Minoru Sakurai ¹ , Michel Seigneuret ³ , and <u>Toshihisa Ishikawa</u> ¹
	<i>¹Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan, ²JSPS Research Fellow, and ³CNRS (UMR 8104) INSERM (U567), Université Paris, France</i>
86	Quantitative expression profiling of 29 human transporter proteins in Caco-2 cells of different culture periods
	<u>Yasuo Uchida</u> ¹ , Junichi Kamiie ^{1,2} , Ryo Iwase ¹ , Ken Ohmine ¹ , Sumio Ohtsuki ^{1,2} , and Tetsuya Terasaki ^{1,2}
	<i>¹Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan, and ²SORST of the Japan Science and Technology Agency, Japan</i>
89	<i>In vitro</i> to <i>in vivo</i> prediction of P-gp based drug interactions at the human blood-brain barrier
	<u>Peng Hsiao</u> ¹ , Sara Eyal ¹ , Mark Muzi ² , Francisco Chung ¹ , Amal Kaddoumi ¹ , Jeanne M Link ² , David A Mankoff ² , Tot Bui ¹ , Rodney JY Ho ¹ , and Jashvant D Unadkat ¹
	<i>¹Department of Pharmaceutics, and ²Department of Radiology, University of Washington, Seattle, Washington, USA</i>

94	Gene expression of ATP-binding cassette transporter A and C subfamilies at the mouse inner blood-retinal barrier
	<u>Masanori Tachikawa</u> , Hidetoh Toki, Masatoshi Tomi, and Ken-ichi Hosoya
	<i>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan</i>
103	Placental transport of erythromycin evaluated using syncytiotrophoblast cell line TR-TBT 18d-1
	<u>Yoshimichi Sai</u> , Kaori Ochi, Noriko Kose, Tomohiro Nishimura, and Emi Nakashima
	<i>Kyoritsu University of Pharmacy, Tokyo, Japan</i>
105	MATE: a mammalian transporter protein that mediate the final excretion step for toxic organic cations
	<u>Yoshinori Moriyama</u> , Takuya Matsumoto, Miki Hiasa, Toshinori Komatsu, Takuji Kanamoto, Ayumi Kobara, Masato Otsuka, and Hiroshi Omote.
	<i>Department of Membrane Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan</i>
108	OCT and MATE families are key transporters in platinum agents-induced nephrotoxicity

	<p>Sachiko Yokoo, Atsushi Yonezawa, Satohiro Masuda, Toshiya Katsura, and Ken-ichi Inui</p>
	<p><i>Department of Pharmacy, Kyoto University Hospital, Kyoto, Japan</i></p>
114	<p>Intestinal absorption of cephalexin is governed by PDZK1 as a regulatory mechanism of oligopeptide transporter PEPT1 (Slc15a1) in mice</p>
	<p>Tomoko Sugiura, Yukio Kato, Yoshiyuki Kubo, and Akira Tsuji</p>
	<p><i>Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, Japan</i></p>